Publications

Here, you can access all publications of the PRISM 2 consortium or as well as background literature. Once new publications are available, we list them here. Open-access papers are linked directly to the full-text version. All others lead to the respective preprint repository or publisher.

PRISM 2 Poster

Demyelination in the Forceps Minor contributes to Changes in Social Behavior. [PDF]

Manipulating a brain circuit associated with sociability by a two-recombinase system. [PDF]
Back translational study: social dysfunction association with Default Mode Network. [PDF]

PRISM 2 Publications (10)

Si et al. (2024). Mapping gray and white matter volume abnormalities in early-onset psychosis: an ENIGMA multicenter voxel-based morphometry study Molecular Psychiatry.

Sideli et al. (2023). The relationship between genetic liability, childhood maltreatment, and IQ: findings from the EU-GEI multicentric case-control study Social psychiatry and psychiatric epidemiology.
Arango (2023). Child maltreatment should be a priority for public mental health interventions European Archives of Psychiatry and Clinical Neuroscience.
Arango et al. (2023). Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: treatment goals and approaches to functional recovery BMC Psychiatry.
Cortese et al. (2023). The future of child and adolescent clinical psychopharmacology: A systematic review of phase 2, 3, or 4 randomized controlled trials of pharmacologic agents without regulatory approval or for unapproved indications. Neuroscience & Biobehavioral Reviews.
Fusar-Poli et al. (2023). Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. Psychiatry Research.
Stella et al. (2023). Analysis of common genetic variation across targets of microRNAs dysregulated both in ASD and epilepsy reveals negative correlation. Frontiers in Genetics.

Szerman et al. (2022). Is there such a thing as gambling dual disorder? Preliminary evidence and clinical profiles. European Neuropsychopharmacology.
Braak et al. (2022). Theory of Mind and social functioning among neuropsychiatric disorders: A transdiagnostic study. European Neuropsychopharmacology.
Bas-Hoogendam et al. (2022). Structural Brain Correlates of Childhood Inhibited Temperament: An ENIGMA-Anxiety Mega-analysis. Journal of the American Academy of Child and Adolescent Psychiatry.

PRISM Publications

Kas et al. (2024): Digital behavioural signatures reveal trans-diagnostic clusters of Schizophrenia and Alzheimer’s disease patients. European Neuropsychopharmacology.

Selected Background Literature

Catalá-López F et al. (2010). Does the development of new medicinal products in the European Union address global and regional health concerns? Popul Health Metr, 8: 34c.
Cuthbert BN and Insel TR (2013). Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med, 11: 126.
Cuthbert BN (2019). The PRISM Project: Social Withdrawal from an RDoC Perspective. Neurosci Biobehav Rev, 97: 34-37.
Insel TR and Cuthbert BN (2015). Brain disorders? Precisely. Science, 348: 499–500.
Kas MJ et al. (2019). A quantitative approach to neuropsychiatry: The why and the how. Neurosci Biobehav Rev, 97: 3–9.
Missault S et al. (2019). Hypersynchronicity in the default mode-like network in a neurodevelopmental animal model with relevance for schizophrenia. Behav Brain Res, 364: 303–316.
Porcelli S et al. (2019). Social brain, social dysfunction and social withdrawal. Neurosci Biobehav Rev, 97: 10–33.
Peleh T et al. (2019). RFID-supported video tracking for automated analysis of social behaviour in groups of mice. J Neurosci Methods, 325: 108323.
Saris IMJ et al (2017). Social functioning in patients with depressive and anxiety disorders. Acta Psychiatr Scand, 136: 352–361.
Zott B et al. (2018). What Happens with the Circuit in Alzheimer’s Disease in Mice and Humans? Annu Rev Neurosci, 41: 277–297.

The PRISM 2 project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101034377. The JU receives support from the European Union’s Horizon 2020 research and innovation programme, EFPIA, and Cohen Veterans Bioscience (CVB). The website reflects only the authors' views and IMI JU, EFPIA, CVB, and the European Commission are not responsible for any use that may be made of the information it contains.

© PRISM 2 consortium 2024